BLASUBCUTANEOUSSOLUTION
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
RITUXAN HYCELA (rituximab and hyaluronidase) by Roche is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2017.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RITUXAN HYCELA is a subcutaneous formulation combining rituximab (a CD20-directed monoclonal antibody) with hyaluronidase, enabling self-administered dosing instead of intravenous infusion. It works by targeting CD20-positive B cells in conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. The hyaluronidase component facilitates subcutaneous delivery, improving patient convenience and potentially reducing healthcare burden.
$0.638MPart D
PeakProduct is in peak lifecycle stage with limited Part D spending, suggesting modest market adoption relative to intravenous rituximab formulations and stronger Roche competitors.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Started Apr 2021
3 enrolled
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular Lymphoma+11 more
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Started Jun 2019
15 enrolled
Cutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IVStage III Melanoma+5 more
Worked on RITUXAN HYCELA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.